6 completed, 3 not yet recruiting, 3 unknown, 2 recruiting. 16 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 6, Not yet recruiting 3, Unknown 3, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
Follow Forxiga: new trials by email Literature Review of Forxiga trials Research Report on Forxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2026-11-01 | 2026-06-22 |
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Not yet recruiting | Seug yun Yoon, MD | 37 | 2026-09-01 | 2026-04-08 |
| Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin FORXIGA - Type 1 Diabetes Mellitus | Phase 2 | Not yet recruiting | St Vincent's Hospital Melbourne | 115 | 2026-02-01 | 2025-11-06 |
| Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity Dapagliflozin 10 MG Oral Tablet, Placebo Oral Tablet - Solid Tumors, Cisplatin Nephrotoxicity | Phase 2 | Recruiting | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 46 | 2025-05-07 | 2026-03-11 |
| A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. Dapagliflozin 10mg Tab, Balcinrenone 50mg Capsule, Balcinrenone 100mg Capsule - Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis | Phase 2 | Completed | Klinikum Nürnberg | 103 | 2023-07-13 | 2026-04-27 |
| SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease Dapagliflozin 10mg Tab, Standard maintenance therapy - Lupus Nephritis, Chronic Kidney Diseases | Phase 2 | Recruiting | The University of Hong Kong | 150 | 2023-01-04 | 2024-12-16 |
| Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction Dapagliflozin - Heart Failure, Reduced Ejection Fraction | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 40 | 2022-06-26 | 2022-12-09 |
| Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients Dapagliflozin 10mg, Glucose Tab - Anterior MI | Phase 2 / Phase 3 | Completed | Omar Younis | 100 | 2021-10-01 | 2024-11-19 |
| Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology Semaglutide, Dapagliflozin - Type2 Diabetes | Phase 2 | Active not recruiting | Region Skane | 200 | 2020-09-10 | 2025-07-16 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms EDP1815, Dapagliflozin, Ambrisentan - COVID-19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 454 | 2020-07-03 | 2023-07-28 |
| Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial Dapagliflozin 10 MG, Placebo oral tablet - Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2 | Phase 2 | Unknown | Damanhour University | 60 | 2020-03-01 | 2020-03-11 |
| Effect of Dapagliflozin on IAH in T1DM Dapagliflozin, Placebo oral capsule - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 2 | Completed | Radboud University Medical Center | 15 | 2018-11-23 | 2020-03-23 |
| Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2. Dapagliflozin 10mg, Saxagliptin 5mg, Saxagliptin 5mg + Dapagliflozin 10 mg - Type2 Diabetes Mellitus | Phase 2 | Completed | University of Pisa | 48 | 2018-07-24 | 2022-11-08 |
| Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia Dapagliflozin 10 MG Oral Tablet - Diabetes Mellitus, Type 1 | Phase 2 | Terminated | University of Oxford | 9 | 2018-06-02 | 2022-05-18 |
| Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Dapagliflozin, Placebo - Metabolic Syndrome X | Phase 2 / Phase 3 | Completed | University of Guadalajara | 24 | 2014-04-01 | 2020-10-28 |
Diabetes Mellitus, Type 1 (3) · Heart Failure (2) · Hypoglycemia (2) · Metabolic Syndrome (2) · Renal Insufficiency, Chronic (2) · Anemia (1) · Anterior Wall Myocardial Infarction (1) · COVID-19 (1) · Cardiomyopathies (1) · Cognitive Dysfunction (1) · Dementia, Vascular (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Fibrosis (1) · Glomerulonephritis (1)
Assistance Publique - Hôpitaux de Paris (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Centre Hospitalier Universitaire de Nice (1) · Damanhour University (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Jaime Daniel Mondragon (1) · Klinikum Nürnberg (1) · Omar Younis (1) · Radboud University Medical Center (1) · Region Skane (1) · Seug yun Yoon, MD (1) · St Vincent's Hospital Melbourne (1) · The University of Hong Kong (1) · University of Guadalajara (1) · University of Oxford (1)
France (3) · Mexico (3) · United Kingdom (2) · Australia (1) · Egypt (1) · Germany (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Sweden (1)
Adriana Marton, MD (1) · Anders Rosengren (1) · Desmond Yap, MD (HK) (1) · Ioannis Spiliotis, MD (1) · Joseph Cheriyan, MBChB MA FRCP (1) · Khairy Abdul-Dayem, M.D. (1)
PMID 31535829, PMID 18599344, PMID 20204386, PMID 20980548, PMID 21398642, PMID 23040716, PMID 25424969, PMID 26378978, PMID 28095900, PMID 28605608, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29573529, PMID 30689697, PMID 30935417, PMID 31236801, PMID 31248555, PMID 31707794, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32736592, PMID 32854852, PMID 32865377, PMID 32877652, PMID 33030307, PMID 33282811, PMID 33894597, PMID 34473343, PMID 34813630, PMID 36889650, PMID 38177805, PMID 38334499, PMID 39844769, PMID 41854743, PMID 8443896, PMID 9789568
2017 (1), U01DK143330 (1)